JDRF in the Globe and Mail, November 25, 2014: For kids, research and new treatment options bring less discomfort and better outcomes
JDRF showcases advancements in CGM technology in making monitoring of glucose levels better and the new experimental encapsulated cell replacement therapy.
First Ever Person with Type 1 Diabetes Receives Experimental Encapsulated Human Stem Cell-Derived Beta Cell Replacement Therapy
JDRF showcases advancements in T1D pregnancy care; highlighting JDRF CCTN and the CONCEPTT Trial, and exploring the challenges of managing T1D through pregnancy.
40 Kids and Country Superstar George Canyon Step up to Cure Type 1 Diabetes (T1D) JDRF Ambassadors head to Parliament Hill to discuss the importance of funding research
Lilly Canada provided JDRF with $220,000 in 2013-2014 in support of the creation of a national clinical training program to enable young investigators to further engage in medical research associated with type 1 diabetes.
Sun Life Financial and the Canadian Football League (CFL) partner to raise up to $100,000 for JDRF
JDRF’s partner ViaCyte recently announced the U.S. Food and Drug Administration (FDA) is allowing them to move forward with a clinical trial of its innovative type 1 diabetes (T1D) encapsulated cell replacement therapy called VC-01™ product candidate.
JDRF Partner ViaCyte Announces Key Project Milestone to Advance Innovative Encapsulated Cell Replacement Therapy Product for Type 1 Diabetes
To address the need for education on how patients with type 1 diabetes (T1D) can pursue physical activity safely, Novo Nordisk has committed to a three-year, $5 million grant in support of a new JDRF Outreach initiative titled “T1D Performance in Exercise and Knowledge ...
JDRF and the Innovative Medicines Initiative (IMI) have partnered on a new precompetitive type 1 diabetes research consortium entitled “TRANSLATIONAL APPROACHES TO DISEASE MODIFYING THERAPY OF TYPE 1 DIABETES MELLITUS (T1DM)”.